Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide in Advanced Cephalic and Cervical Adenoid Cystic Carcinoma
NCT02883374Phase 2Unknown
- Sponsor
- Dongmei Pharmaceutical
- Start
- Nov 2016
- Primary completion
- Jun 2020
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in adenoid cystic carcinoma (ACC), sponsored by Dongmei Pharmaceutical. Primary endpoint: Disease Control Rate at 33 months. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT02883374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02883374.